Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H18N2.ClH |
Molecular Weight | 262.778 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CC=C2N3CCNC4CCCC(C2=C1)=C34
InChI
InChIKey=LIFOOCLGAAEVIF-UHFFFAOYSA-N
InChI=1S/C15H18N2.ClH/c1-10-5-6-14-12(9-10)11-3-2-4-13-15(11)17(14)8-7-16-13;/h5-6,9,13,16H,2-4,7-8H2,1H3;1H
Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A). It exerts an inhibitory effect on noradrenaline and 5-hydroxytryptamine reuptakes. It has no effect on the dopaminergic and cholinergic systems. It has only a low potential for amplifying tyramine and noradrenaline pressor effect, which makes one expect that it will not be at the basis of a ‘cheese effect’. Pirlindole was approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treatment of depression. The drug's efficacy and safety have also been demonstrated in the treatment of fibromyalgia syndrome. Pirlindole has a favorable tolerability profile, with no deleterious effect on cardiovascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Pirlindole prevented qualitative alteration (transformation) in the catalytic activity of membrane-bound type A monoamine oxidases (MAO-A), pathogenetically important for the development of the audiogenic seizures.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564636 |
PubMed
Title | Date | PubMed |
---|---|---|
An MCASE approach to the search of a cure for Parkinson's Disease. | 2002 Apr 2 |
|
Automated determination of pirlindole enantiomers in plasma by on-line coupling of a pre-column packed with restricted access material to a chiral liquid chromatographic column. | 2002 Jan 15 |
|
[Pyrazidol in the treatment of depression in patients with ischemic heart disease]. | 2003 |
|
[The experience of pyrazidol use in the treatment of non-psychotic depression]. | 2003 |
|
[Pirasidol in clinical practice]. | 2003 |
|
Pre- and post-treatment with pirlindole and dehydropirlindole protects cultured brain cells against nitric oxide-induced death. | 2003 Apr 11 |
|
Monoamine oxidases: to inhibit or not to inhibit. | 2003 Mar |
|
Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B). | 2011 Oct 27 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
240-307-9
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY | |||
|
100000128478
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY | |||
|
115141
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY | |||
|
SUB35547
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY | |||
|
16154-78-2
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY | |||
|
DBSALT002870
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY | |||
|
Q89W8I397C
Created by
admin on Sat Dec 16 09:42:09 GMT 2023 , Edited by admin on Sat Dec 16 09:42:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD